On 2nd July 2018, Ocugen launched Phase III trials for its OCU300 nanoemulsion intended for treatment against the symptoms of ocular graft versus host disease (oGVHD). Ocugen is a Malvern, Pennsylvania based company and possess a nanoemulsion formulation of brimonidine tartrate (OCU300) in its pipeline. The Company has also claimed that its first oGVHD ( therapy entering in Phase III clinical trial and its ophthalmic comorbidity impacts 60% of people who have an allogeneic bone marrow transplant.

Ocugen is carrying out an observational study in which around 90% of the people suffering with oGVHD used Ocugen’s eye drops for six months reported development in their recovery without any serious side effects. In Phase I/II trial it’s been reported that people using the brominidine eye drops experienced swift reduction in ocular redness compared to people using placebo. The Company also announced that the data related with Phase III trials will be shared in second half of 2019.

Analyst View:

The application range of nanoemulsion technology is increasing significantly and the drug delivery process is enhancing due to incessant research and development in this field. Thus, enhancing performance of ocular therapy is just one of the developments observed about nanoemulsions its other advantages have boosted several antimicrobial and oncology drugs to reformulate the drugs with this technology to achieve higher bioavailability coupled with drug efficacy.